These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 18027207)

  • 1. Adaptive designs in clinical drug development: opportunities, challenges, and scope reflections following PhRMA's November 2006 workshop.
    Krams M; Burman CF; Dragalin V; Gaydos B; Grieve AP; Pinheiro J; Maurer W; Gallo P
    J Biopharm Stat; 2007; 17(6):957-64. PubMed ID: 18027207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adaptive designs in clinical drug development--an Executive Summary of the PhRMA Working Group.
    Gallo P; Chuang-Stein C; Dragalin V; Gaydos B; Krams M; Pinheiro J;
    J Biopharm Stat; 2006 May; 16(3):275-83; discussion 285-91, 293-8, 311-2. PubMed ID: 16724485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA draft guidance on adaptive design clinical trials: Pfizer's perspective.
    Chuang-Stein C; Beltangady M
    J Biopharm Stat; 2010 Nov; 20(6):1143-9. PubMed ID: 21058110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Innovative approaches for designing and analyzing adaptive dose-ranging trials.
    Bornkamp B; Bretz F; Dmitrienko A; Enas G; Gaydos B; Hsu CH; König F; Krams M; Liu Q; Neuenschwander B; Parke T; Pinheiro J; Roy A; Sax R; Shen F
    J Biopharm Stat; 2007; 17(6):965-95. PubMed ID: 18027208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA signals it's open to drug trials that shift midcourse.
    Mathews AW
    Wall St J (East Ed); 2006 Jul; ():B1, B8. PubMed ID: 16858817
    [No Abstract]   [Full Text] [Related]  

  • 6. Discussion of the "White Paper of the PhRMA Working Group on adaptive dose-ranging designs".
    Grieve AP
    J Biopharm Stat; 2007; 17(6):997-1004; discussion 1029-32. PubMed ID: 18027209
    [No Abstract]   [Full Text] [Related]  

  • 7. Barriers and opportunities for implementation of adaptive designs in pharmaceutical product development.
    Quinlan J; Gaydos B; Maca J; Krams M
    Clin Trials; 2010 Apr; 7(2):167-73. PubMed ID: 20338900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of draft FDA adaptive design guidance.
    Cook T; DeMets DL
    J Biopharm Stat; 2010 Nov; 20(6):1132-42. PubMed ID: 21058109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viewpoints on the FDA draft adaptive designs guidance from the PhRMA working group.
    Gallo P; Anderson K; Chuang-Stein C; Dragalin V; Gaydos B; Krams M; Pinheiro J
    J Biopharm Stat; 2010 Nov; 20(6):1115-24. PubMed ID: 21058107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Innovative approaches in drug development.
    Chang M; Kenley S; Bull J; Chiu YY; Wang W; Wakeford C; McCarthy K
    J Biopharm Stat; 2007; 17(5):775-89. PubMed ID: 17885865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discussion of the paper "Adaptive dose-ranging designs".
    Burman CF
    J Biopharm Stat; 2007; 17(6):1005-11; discussion 1029-32. PubMed ID: 18027210
    [No Abstract]   [Full Text] [Related]  

  • 12. Understanding the FDA guidance on adaptive designs: historical, legal, and statistical perspectives.
    Liu Q; Chi GY
    J Biopharm Stat; 2010 Nov; 20(6):1178-219. PubMed ID: 21058114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On flexibility of adaptive designs and criteria for choosing a good one--a discussion of FDA draft guidance.
    Cheng B; Chow SC
    J Biopharm Stat; 2010 Nov; 20(6):1171-7. PubMed ID: 21058113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adaptive methods: telling "the rest of the story".
    Emerson SS; Fleming TR
    J Biopharm Stat; 2010 Nov; 20(6):1150-65. PubMed ID: 21058111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptive design in clinical research: issues, opportunities, and recommendations.
    Chang M; Chow SC; Pong A
    J Biopharm Stat; 2006 May; 16(3):299-309; discussion 311-2. PubMed ID: 16724486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discussion of "The White Paper of the PhRMA Working Group on adaptive dose-ranging designs".
    Hemmings R
    J Biopharm Stat; 2007; 17(6):1021-7; discussion 1029-32. PubMed ID: 18027213
    [No Abstract]   [Full Text] [Related]  

  • 17. Editorial: Adaptive designs: appealing in development of therapeutics, and where do controversies lie?
    Wang SJ
    J Biopharm Stat; 2010 Nov; 20(6):1083-7. PubMed ID: 21058102
    [No Abstract]   [Full Text] [Related]  

  • 18. Discussion of the "White Paper of the PhRMA PISC Working Group on adaptive dose-ranging designs".
    Leonov S
    J Biopharm Stat; 2007; 17(6):1013-4; discussion 1029-32. PubMed ID: 18027211
    [No Abstract]   [Full Text] [Related]  

  • 19. A note on special articles on adaptive clinical trial designs.
    Chow SC
    J Biopharm Stat; 2010 Nov; 20(6):1088-9. PubMed ID: 21058103
    [No Abstract]   [Full Text] [Related]  

  • 20. Comments on the FDA draft guidance on adaptive designs.
    Wittes J
    J Biopharm Stat; 2010 Nov; 20(6):1166-70. PubMed ID: 21058112
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.